Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Windtree Therapeutics stock

Learn how to easily invest in Windtree Therapeutics stock.

Windtree Therapeutics Inc is a biotechnology business based in the US. Windtree Therapeutics shares (WINT) are listed on the NASDAQ and all prices are listed in US Dollars. Windtree Therapeutics employs 33 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Windtree Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – WINT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Windtree Therapeutics stock price (NASDAQ: WINT)

Use our graph to track the performance of WINT stocks over time.

Windtree Therapeutics shares at a glance

Information last updated 2022-07-02.
Latest market close$0.46
52-week range$0.38 - $2.40
50-day moving average $0.55
200-day moving average $1.24
Wall St. target price$3.40
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.44

Buy Windtree Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you open a Robinhood account
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Windtree Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Windtree Therapeutics price performance over time

Historical closes compared with the close of $0.4641 from 2022-07-06

1 week (2022-06-30) 10.50%
1 month (2022-06-07) -1.46%
3 months (2022-04-03) N/A
6 months (2022-01-06) -67.77%
1 year (2021-07-07) -77.47%
2 years (2020-07-07) -93.37%
3 years (2019-07-03) N/A
5 years (2017-07-07) 62.84%

Windtree Therapeutics financials

Gross profit TTM $-17,787,000
Return on assets TTM -19.16%
Return on equity TTM -105.85%
Profit margin 0%
Book value $1.22
Market capitalisation $12.5 million

TTM: trailing 12 months

Windtree Therapeutics share dividends

We're not expecting Windtree Therapeutics to pay a dividend over the next 12 months.

Have Windtree Therapeutics's shares ever split?

Windtree Therapeutics's shares were split on a 1:3 basis on 28 April 2020. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Windtree Therapeutics shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Windtree Therapeutics shares which in turn could have impacted Windtree Therapeutics's share price.

Windtree Therapeutics share price volatility

Over the last 12 months, Windtree Therapeutics's shares have ranged in value from as little as $0.38 up to $2.4. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Windtree Therapeutics's is 0.2799. This would suggest that Windtree Therapeutics's shares are less volatile than average (for this exchange).

Windtree Therapeutics overview

Windtree Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S. A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program.

Frequently asked questions

What percentage of Windtree Therapeutics is owned by insiders or institutions?
Currently 30.383% of Windtree Therapeutics shares are held by insiders and 5.19% by institutions.
How many people work for Windtree Therapeutics?
Latest data suggests 33 work at Windtree Therapeutics.
When does the fiscal year end for Windtree Therapeutics?
Windtree Therapeutics's fiscal year ends in December.
Where is Windtree Therapeutics based?
Windtree Therapeutics's address is: 2600 Kelly Road, Warrington, PA, United States, 18976-3622
What is Windtree Therapeutics's ISIN number?
Windtree Therapeutics's international securities identification number is: US97382D3035
What is Windtree Therapeutics's CUSIP number?
Windtree Therapeutics's Committee on Uniform Securities Identification Procedures number is: 036338101

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site